Ruemu Birhiray is an Oncology physician affiliated with The US Oncology Network. OpenAlex indexes 62 publications with 1,856 citations (h-index 11).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
8301 Harcourt Rd
Suite #200
Indianapolis, IN 462602081
Telephone
317-415-6600Provider last certified this registry record 30 Dec 2022.
Industry payments
101 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year202570 payments$77,362openpaymentsdata.cms.gov ↗
- Incyte CorporationProgram year202548 payments$66,231openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year202541 payments$64,683openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
39.2%Substance P/Neurokinin-1 Receptor Antagonist34.8%Aprepitant100%Part B, office-administered≥33 patientsSerotonin-3 Receptor Antagonist4%Palonosetron hcl74%Ondansetron hydrochloride22%Ondansetron Odt2%Ondansetron Hcl2%Part D + Part B≥34 patients+ 5 more classes in this area
Musculoskeletal
33%RANK Ligand Inhibitor32.4%Denosumab100%Part B, office-administered≥132 patientsBisphosphonate0.6%Zoledronic acid100%Part B, office-administered≥47 patientsBlood & clotting
19%Erythropoiesis-stimulating Agent13.9%Epoetin alfa100%Part B, office-administered≥21 patientsIron, parenteral preparations4.9%Ferric derisomaltose100%Part B, office-administered≥24 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A review of representation in clinical trials for metastatic prostate carcinoma.
Journal of Clinical Oncology
2026
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”